|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
Description: Number of participants that require ECMO Number of participants that cannot be extubated within 10 days or A downward change in Oxygenation Index by >15% from baselineMeasure: Reduction in Respiratory Failure Time: 10 days
Description: Number of participants that require ECMO Number of participants requiring inotropic therapy Number of participants that require mechanical circulatory support A change in Cardiac Troponin >20% from baseline or A change in BNP >15% from baselineMeasure: Reduction in Cardiac/Circulatory Failure Time: 10 days
Description: Number of participants that demonstrate a change in FiO2 by 50% or more.Measure: Improvement in Oxygenation Time: 10 days
Description: Number of participants with a reduction in the time to extubation Number of participants with a reduction in ICU days Number of participants with a reduction in hospital daysMeasure: Improved Clinical Outcomes Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports